Antimicrobial resistance in the Netherlands is remaining reasonably stable Antimicrobial resistance is increasing on a global level. It is difficult to treat infections caused by resistant bacteria.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
The Dutch Diet is slightly healthier Recent years show a cautious improvement in the Dutch diet. The Dutch have started to eat more fruit and it seems to be heading in the right direction with vegetables.
Disease burden and cost-of-illness of food-related pathogens in the Netherlands Each year, RIVM presents an update on the number of illnesses caused by 14 enteric pathogens (such as Salmonella, Campylobacter or Listeria) that can be transmitted by food into the human body.
First products Dutch Public Health Foresight study available in English In 2017, RIVM launched a Trend Scenario, as well as three thematic reports about the future demand for health care, technology and wider determinants of health.
Chance of ESBL contamination via livestock farming is small ESBL is an enzyme, produced by certain bacteria, which makes these bacteria resistant to antibiotics.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Trend scenario PHF- 2018 identifies societal challenges for the future If historical trends continue unchanged, dementia will be the leading cause of disease burden in 2040 and the main cause of death.
Alertness about the Zika virus still needed for pregnant women Since May 2015, there has been a Zika virus outbreak in South and Central America, including the Caribbean. The Zika virus can cause birth defects, including microcephaly (small head size).
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.